Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

52 week Range -
/

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

Symbol Name Last Price Change % Change

Cannin’s Top 5 Cannabis Stocks to Watch Now

Cannabis stocks in the U.S. markets are poised to deliver market-beating returns to long-term investors given the recent wave of legalization across several states. Additionally, if marijuana is legalized at the federal level for recreational and medicinal use,...

Urban-Gro: Is this Cannabis Stock a Strong Buy?

With a 2021 IPO sending the stock soaring to 400%, Urban-Gro should definitely be on the minds of every cannabis stock investor. But is Urban-Gro cannabis stock a strong buy? Urban-Gro (Nasdaq: UGRO) supports cultivation facilities by performing design, architectural,...

3 Reasons Why IIPR Will Outperform Marijuana Stocks in 2021

Throughout much of 2021, marijuana stocks have been under substantial pressure amid market volatility. However, Canadian-based REIT, Innovative Industrial Properties (IIPR) continues to outperform as the marijuana stock surged over 32% in 2021. But what are the 3...

3 Volatile Large-Cap Hemp Stocks to Watch for 2021

3 Volatile Large-Cap Hemp Stocks to Watch for 2021 Given everpresent market volatility, it's become pretty clear that investing in cannabis and hemp stocks is a long-term play. There are several fundamental issues impacting the cannabis industry which will mean hemp...

22nd Century: Is this Cannabis Stock a Buy and Hold?

22nd Century Group (Nasdaq: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing, and modern plant...

Why is VFF a strong buy?

After rebalancing our portfolios this week, we've got exciting news about several new opportunities. We are particularly excited about Village Farms International (VFF). Keep reading to see why VFF is a strong buy. As you know, Cannin's Cannabis Stock Portfolios track...

With Colombia on the Rise is PharmaCielo Stock a Buy?

In an increasingly globalized cannabis market, Colombia continues to make headlines. In fact, this July, Colombian President Ivan Duque gave the Colombian cannabis industry a huge bump by signing a directive to allow for the export of dried cannabis flower. Several...

Should You Add HempAmericana Stock to Your Watchlist?

As you may know, the analysts at Cannin are constantly evaluating the next best hemp stock investment opportunities. With HempAmericana, Inc. (HMPQ) gaining 10% on the week, we wanted to cover this hemp stock for our audience. But should you add HempAmericana stock to...

Is Claritas Pharmaceuticals a Good Investment?

We continue to see plenty of chatter on social media about Claritas Pharmaceuticals so we figured we would go ahead and do a deep dive fundamental analysis on the company. But is Claritas Pharmaceuticals a good investment? Let's take a closer look at the fundamentals...

Should You Buy Agrify Stock?

With solid fundamentals and a recent acquisition of industry titans Precision Extraction and Cascade Biosciences, the future is looking incredibly bright for cannabis ancillary Agrify Corporation (NASDAQ: AGFY). But should you buy Agrify stock? Indeed, the stock is up...